Provided by Tiger Trade Technology Pte. Ltd.

MiNK Therapeutics, Inc.

12.44
-0.2900-2.28%
Post-market: 12.620.1800+1.45%19:33 EDT
Volume:48.87K
Turnover:610.23K
Market Cap:63.48M
PE:-5.19
High:12.72
Open:12.72
Low:12.10
Close:12.73
52wk High:16.93
52wk Low:8.48
Shares:5.10M
Float Shares:2.07M
Volume Ratio:1.81
T/O Rate:2.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3970
EPS(LYR):-2.9257
ROE:-1238.98%
ROA:-123.84%
PB:-4.53
PE(LYR):-4.25

Loading ...

Mink Therapeutics shareholders approve KPMG as auditor

Reuters
·
Jun 23

MiNK Therapeutics Rocked by Fresh Insider Share Sale

TIPRANKS
·
Jun 06

MiNK Therapeutics director Barbara Ryan disposes of 1,500 common shares worth $19,143.25

Reuters
·
Jun 06

MiNK Therapeutics announces virtual annual shareholders meeting

Reuters
·
Jun 04

MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting

GlobeNewswire
·
Jun 04

BUZZ-U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's

Reuters
·
May 29

MiNK Therapeutics doses first patient in agenT-797 trial

TIPRANKS
·
May 28

BUZZ-MiNK Therapeutics jumps after first patient dosed in lung injury study

Reuters
·
May 28

Mink Therapeutics doses first patient in Phase 2 agenT-797 acute lung injury trial

Reuters
·
May 28

Mink Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury and Critical Illness

THOMSON REUTERS
·
May 28

MiNK Therapeutics reports new data on agenT-797 at ATS 2026

TIPRANKS
·
May 20

Mink Therapeutics starts Phase 2 trial of agenT-797 in severe acute lung injury

Reuters
·
May 20

MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications

GlobeNewswire
·
May 20

MiNK Therapeutics Price Target Maintained With a $35.00/Share by HC Wainwright & Co.

Dow Jones
·
May 18

Analysts Are Bullish on These Healthcare Stocks: Biofrontera (BFRI), MiNK Therapeutics (INKT)

TIPRANKS
·
May 18

Mink Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

MiNK Therapeutics Q1 EPS $(0.57) Beats $(0.78) Estimate

Benzinga Earnings
·
May 15

MiNK Therapeutics Q1 FY26 net loss narrows to $2.74 million

Reuters
·
May 15

BRIEF-MiNK Therapeutics Q1 EPS USD -0.57

Reuters
·
May 15

Mink Therapeutics Q1 EPS USD -0.57

THOMSON REUTERS
·
May 15